LEAP THERAPEUTICS, INC.
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
LPTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 47 THORNDIKE STREET, 2142 CAMBRIDGE
- Website:
- https://www.leaptx.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics to treat cancer. The company's most advanced clinical candidate is DKN-01 (sirexatamab), a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. Leap's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and the preclinical candidate FL-501, which targets the GDF-15 protein. The company's mission is to discover and develop novel therapies and combinations against new biological targets in oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all LEAP THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for LEAP THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for LEAP THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
